Benzinga - Gainers
- Ibio Inc (NYSE: IBIO) shares rose 162.6% to $1.97 in pre-market trading after dropping around 12% on Thursday. JMP Securities, on Thursday, downgraded iBio from Market Outperform to Market Perform.
- Nogin Inc (NASDAQ: NOGN) rose 76.6% to $1.08 in pre-market trading after the company and Seychelles Imports LLC announced an agreement under which Sychelles will utilize Nogin's Customer Data Platform and Marketing Automation and Marketplace Dropship.
- Universal Security Instruments, Inc. (NYSE: UUU) rose 21.1% to $2.66 in pre-market trading after the company reported a year-over-year increase in Q3 EPS and revenues.
- Meta Materials Inc (NASDAQ: MMAT) rose 18.8% to $0.87 in pre-market trading after the company received new purchase order from its G10 central bank customer.
- Heliogen Inc (NYSE: HLGN) shares rose 13.5% to $0.41 in pre-market trading. Heliogen, in update letter to shareholders, said it hopes to create shareholder value necessary to regain NYSE compliance without need for reverse stock split.
- Bark Inc (NYSE: BARK) shares rose 10.2% to $1.73 in pre-market trading after gaining 8% on Thursday. BARK CFO Zahir Ibrahim acquired a total of 100,000 shares at an average price of $1.55.
- Jasper Therapeutics Inc (NASDAQ: JSPR) rose 7.7% to $1.97 in pre-market trading after the company reported follow-up clinical data from investigator-sponsored study of briquilimab conditioning in sickle cell disease patients.
- VEON Ltd (NASDAQ: VEON) rose 7.6% to $0.77 in pre-market trading after dropping around 9% on Thursday. Veon recently received Russian regulatory approval for the proposed sale of its Russian operations.
- DoorDash Inc (NYSE: DASH) rose 6.7% to $71.37 in pre-market trading after the company reported better-than-expected Q4 revenues and announced a $750 million buyback program.
- Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) rose 4.6% to $0.86 in pre-market trading after declining around 7% on Thursday. Spectrum Pharmaceuticals recently received permanent J-Code for ROLVEDON injection (J1449) from US Centers For Medicare & Medicaid Services.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers- VolitionRX Ltd (NASDAQ: VNRX) shares fell 18.4% to $1.66 in pre-market trading after the company reported a proposed underwritten public offering of common stock.
- XP Inc (NASDAQ: XP) shares dropped 13.1% to $13.82 in pre-market trading after the company reported a drop in Q4 net revenue.
- Pop Culture Group Co Ltd (NASDAQ: CPOP) fell 12% to $0.88 in pre-market trading.
- Ambrx Biopharma Inc - ADR (NYSE: AMAM) fell 11.5% to $2.46 in pre-market trading. Ambrx Biopharma shares jumped 56% on Thursday after the company announced initial data from its ongoing Phase 1 APEX-01 trial of ARX517, Ambrx's proprietary anti-PSMA ADC, in prostate cancer patients.
- Stem Inc (NYSE: STEM) fell 11.1% to $8.66 in pre-market after the company reported worse-than-expected Q4 results.
- Axcella Health Inc (NASDAQ: AXLA) fell 10.4% to $0.65 in pre-market trading. Axcella shares climbed over 19% on Thursday after the company announced FDA clearance of its IND application to initiate a phase 2b/3 trial in the U.S. for AXA1125.
- Applied Therapeutics Inc (NASDAQ: APLT) shares fell 10.3% to $1.05 in pre-market trading after gaining 17% on Thursday. Applied Therapeutics announced sorbitol reduction data from the ongoing global Phase 3 INSPIRE trial of oral AT-007 in approximately 50 patients with SORD Deficiency in the U.S. and Europe.
- Nextplay Technologies Inc (NASDAQ: NXTP) fell 9.5% to $2.00 in pre-market trading. NextPlay, last month, announced a 1-for-20 reverse stock split.
- Boxed Inc (NYSE: BOXD) fell 9.1% to $0.65 in pre-market trading after jumping 63% on Thursday.
- Natwest Group PLC - ADR (NYSE: NWG) fell 8.2% to $6.84 in pre-market trading. NatWest Group Q4 clocked a 42.5% year-over-year total income growth to £3.71 billion.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.